BTIG Initiates Coverage On Passage Bio with Buy Rating, Announces Price Target of $25
BTIG analyst Yun Zhong initiates coverage on Passage Bio (NASDAQ:PASG) with a Buy rating and announces Price Target of $25.
The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation
Biotech stocks advanced in the week ended May 21, as risk aversion forced traders to buy into defensives. As earnings news flow tapered, stocks took cues from clinical readouts.
50 Biggest Movers From Yesterday
Gainers
MoSys, Inc. (NASDAQ: MOSY) shares jumped 44.1% to settle at $5.46 on Wednesday.
Lianluo Smart Limited (NASDAQ: LLIT) gained 24.6% to settle at $9.22.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.